Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
About
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
This grant program is designed for researchers and clinical research organizations focused on advancing the scientific rigor of clinical trials involving rapid-acting psychotropic interventional drugs (RAPIDs). The funding supports studies that address methodological challenges unique to RAPID clinical trials, including trial design optimization, monitoring protocols, and the integration of adjunctive psychosocial interventions. Researchers applying should have expertise in clinical trial methodology, psychiatry, or psychopharmacology. This R01 Clinical Trial Required grant is particularly valuable for investigators seeking to enhance the interpretability and generalizability of RAPID research outcomes. Organizations should apply if they aim to improve how these fast-acting psychiatric treatments are tested, delivered, and sustained in real-world settings. The program emphasizes rigorous study design that ultimately strengthens the evidence base for rapid-acting psychotropic interventions. By funding methodologically sound research, this initiative helps advance the field's understanding of therapeutic mechanisms and optimal implementation strategies. U.S.-based organizations and domestic entities are eligible to pursue this opportunity through the National Institutes of Health.
Funding Facts
● Applications openDeadline
October 11, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle and project scope
Deadline
2026-10-11
Grant Type
federal
Application Cycle
Annual with October 11, 2026 deadline
Best For
Research institutions, universities, clinical research organizations, and investigators focused on psychiatric treatment methodology and rapid-acting psychotropic drug clinical trials
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Frequently Asked Questions
Who is eligible for Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)?
U.S.-based organizations and domestic entities are eligible to apply. Non-domestic (non-U.S.) entities, foreign organizations, and non-domestic components of U.S. organizations are not eligible. Foreign components are also not allowed. For complete eligibility details, including institutional requirements and researcher qualifications, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.
How much funding does Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required) provide?
Funding amounts vary and are not specified in the current available information. Visit the official NIH NOFO page for detailed information about funding ranges, budget limits, and project period details for this R01 clinical trial grant.
How do I apply for Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)?
Applications are typically submitted through Grants.gov or the NIH eRA Commons system. Your institution's grants office can assist with the submission process. The application deadline is October 11, 2026. For specific application procedures, required forms, and submission guidelines, consult the official NOFO and the NIH grants website.
What can Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required) funding be used for?
Funding supports research that addresses methodological challenges in clinical trials of rapid-acting psychotropic interventional drugs. This includes studies on trial design rigor, therapeutic effect components, optimal delivery and monitoring of RAPIDs, adjunctive psychosocial interventions, and strategies to enhance effectiveness and generalizability of results. The goal is to increase data interpretability and improve real-world implementation outcomes.
Last updated: July 5, 2026